{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:34:20Z","timestamp":1789875260549,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.bioorg.2018.01.040","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T13:03:45Z","timestamp":1517490225000},"page":"393-401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["Synthesis of benzimidazole-linked-1,3,4-oxadiazole carboxamides as GSK-3\u03b2 inhibitors with in vivo antidepressant activity"],"prefix":"10.1016","volume":"77","author":[{"given":"Mushtaq A.","family":"Tantray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinna","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Sarwar","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet","family":"Dhulap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abul","family":"Kalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2018.01.040_b0005","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2174\/1389450110607011377","article-title":"Glycogen synthase kinase-3\u2013an overview of an over-achieving protein kinase","volume":"7","author":"Kockeritz","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bioorg.2018.01.040_b0010","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1074\/jbc.M114.594952","article-title":"Phosphorylation and inactivation of GSK3\u03b2 by dual-specificity tyrosine(Y)-phosphorylation-regulated kinase 1A (Dyrk1A)","volume":"290","author":"Song","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2018.01.040_b0015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ejmech.2016.09.058","article-title":"Natural and synthetic bioactive inhibitors of glycogen synthase kinase","volume":"125","author":"Khan","year":"2017","journal-title":"Euro. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.01.040_b0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuropharm.2017.01.020","article-title":"Glycogen synthase kinase 3 beta alters anxiety-, depression-, and addiction-related behaviors and neuronal activity in the nucleus accumbens shell","volume":"117","author":"Crofton","year":"2017","journal-title":"Neuropharmacol."},{"key":"10.1016\/j.bioorg.2018.01.040_b0025","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/gbb.12283","article-title":"GSK3\u03b2 isoform-selective regulation of depression, memory and hippocampal cell proliferation","volume":"15","author":"Pardo","year":"2016","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.bioorg.2018.01.040_b0030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2018.01.040_b0035","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.encep.2016.02.003","article-title":"The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature","volume":"42","author":"Costemale-Lacoste","year":"2016","journal-title":"Encephale."},{"key":"10.1016\/j.bioorg.2018.01.040_b0040","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jad.2017.02.023","article-title":"The interaction of GSK3B and FXR1 genotypes may influence the mania and depression dimensions in mood disorders","volume":"213","author":"Bureau","year":"2017","journal-title":"J Affect. Disord."},{"key":"10.1016\/j.bioorg.2018.01.040_b0045","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.neuropharm.2016.12.019","article-title":"The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis","volume":"116","author":"P\u00e9rez-Domper","year":"2017","journal-title":"Neuropharmacol."},{"key":"10.1016\/j.bioorg.2018.01.040_b0050","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.mp.4001518","article-title":"Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers","volume":"9","author":"Gould","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bioorg.2018.01.040_b0055","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cell.2007.11.041","article-title":"A beta-arrestin 2 signaling complex mediates lithium action on behavior","volume":"132","author":"Beaulieu","year":"2008","journal-title":"Cell."},{"key":"10.1016\/j.bioorg.2018.01.040_b0060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4088\/JCP.v65n0103","article-title":"Glycogen synthase kinase-3: a target for novel bipolar disorder treatments","volume":"65","author":"Gould","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bioorg.2018.01.040_b0065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1017\/S1461145704004535","article-title":"AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test","volume":"7","author":"Gould","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bioorg.2018.01.040_b0070","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.pnpbp.2008.05.020","article-title":"Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice","volume":"32","author":"Rosa","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bioorg.2018.01.040_b0075","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.biopsych.2004.01.008","article-title":"Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus","volume":"55","author":"Kaidanovich-Beilin","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bioorg.2018.01.040_b0080","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1146\/annurev.pharmtox.011008.145634","article-title":"Akt\/GSK3 signaling in the action of psychotropic drugs","volume":"49","author":"Beaulieu","year":"2009","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bioorg.2018.01.040_b0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/npp.2011.198","article-title":"Review of pharmacological treatment in mood disorders and future directions for drug development","volume":"37","author":"Li","year":"2012","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.bioorg.2018.01.040_b0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1503\/jpn.110011","article-title":"A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health","volume":"37","author":"Beaulieu","year":"2012","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.bioorg.2018.01.040_b0095","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bioorg.2016.07.007","article-title":"Synthesis of pyrimidin-4-one-1,2,3-triazole conjugates as glycogen synthase kinase-3\u03b2 inhibitors with anti-depressant activity","volume":"68","author":"Khan","year":"2016","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2018.01.040_b0100","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/cbdd.12710","article-title":"Synthesis of novel pyrimidin-4-one bearing piperazine ring-based amides as glycogen synthase kinase-3\u03b2 inhibitors with antidepressant activity","volume":"87","author":"Khan","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2018.01.040_b0105","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/cbdd.12724","article-title":"Synthesis of novel oxazolo[4,5-b]pyridine-2-one based 1,2,3-triazoles as glycogen synthase kinase-3\u03b2 inhibitors with anti-inflammatory potential","volume":"87","author":"Tantray","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2018.01.040_b0110","doi-asserted-by":"crossref","first-page":"43345","DOI":"10.1039\/C6RA07273A","article-title":"Synthesis of benzimidazole-based 1,3,4-oxadiazole-1,2,3-triazole conjugates as glycogen synthase kinase-3[small beta] inhibitors with antidepressant activity in in vivo models","volume":"6","author":"Tantray","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2018.01.040_b0115","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1016\/j.bmcl.2016.06.084","article-title":"Synthesis of benzimidazole based thiadiazole and carbohydrazide conjugates as glycogen synthase kinase-3\u03b2 inhibitors with anti-depressant activity","volume":"26","author":"Khan","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2018.01.040_b0120","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1039\/C5NJ02896E","article-title":"Synthesis of Aryl anilinomaleimide based derivatives as glycogen synthase kinase-3[small beta] inhibitors with potential role as antidepressant agents","volume":"40","author":"Tantray","year":"2016","journal-title":"New J. Chem."},{"key":"10.1016\/j.bioorg.2018.01.040_b0125","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.bmc.2009.01.019","article-title":"Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3\u03b2","volume":"17","author":"Saitoh","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.01.040_b0130","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1021\/jm900647e","article-title":"2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3\u03b2 with good brain permeability","volume":"52","author":"Saitoh","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.01.040_b0135","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.1471-4159.2011.07532.x","article-title":"A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S)-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease","volume":"119","author":"Onishi","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bioorg.2018.01.040_b0140","doi-asserted-by":"crossref","first-page":"8534","DOI":"10.1021\/jm100941j","article-title":"Discovery of novel GSK-3beta inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening","volume":"53","author":"Khanfar","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.01.040_b0145","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1021\/jm300309a","article-title":"Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3alpha","volume":"55","author":"Lo Monte","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.01.040_b0150","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1016\/j.bmcl.2007.11.121","article-title":"Novel aryl and heteroaryl substituted N-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamides as selective GSK-3 inhibitors","volume":"18","author":"Koryakova","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2018.01.040_b0155","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1016\/j.bmcl.2007.07.056","article-title":"Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3\u03b2","volume":"17","author":"Shin","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2018.01.040_b0160","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.bmcl.2004.02.036","article-title":"Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors","volume":"14","author":"Peat","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2018.01.040_b0165","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1016\/j.bmc.2006.01.054","article-title":"Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole\/benzoxazole derivatives and some Schiff\u2019s bases","volume":"14","author":"Sondhi","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.01.040_b0170","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ardp.201400219","article-title":"Design and synthesis of benzimidazole analogs endowed with oxadiazole as selective COX-2 inhibitor","volume":"347","author":"Rathore","year":"2014","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.bioorg.2018.01.040_b0175","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/adt.2006.029","article-title":"A high throughput luminescent assay for glycogen synthase kinase-3\u03b2 inhibitors","volume":"5","author":"Baki","year":"2007","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.bioorg.2018.01.040_b0180","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: recent developments and future needs","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2018.01.040_b0185","doi-asserted-by":"crossref","unstructured":"V. Castagne, P. Moser, S. Roux, R.D. Porsolt, Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice, Current protocols in neuroscience\/editorial board, Jacqueline N. Crawley ... [et al.] Chapter 8 (2011) Unit 8 10A.","DOI":"10.1002\/0471142301.ns0810as55"},{"key":"10.1016\/j.bioorg.2018.01.040_b0190","first-page":"348","article-title":"Adaptation of the tail suspension test to the rat","volume":"17","author":"Chermat","year":"1986","journal-title":"J. Pharmacol."},{"key":"10.1016\/j.bioorg.2018.01.040_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyu064","article-title":"A role for galanin N-terminal fragment (1\u201315) in anxiety- and depression-related behaviors in rats","volume":"18","author":"Millon","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206817304881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206817304881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T07:48:38Z","timestamp":1758613718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206817304881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":39,"alternative-id":["S0045206817304881"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2018.01.040","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis of benzimidazole-linked-1,3,4-oxadiazole carboxamides as GSK-3\u03b2 inhibitors with in vivo antidepressant activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2018.01.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}